Breast cancer cells use newfound pathway to survive low oxygen levels in tumors

June 20, 2016
Dr. Benjamin Neel speaks with researchers at Perlmutter Cancer Center.

Researchers have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors. These are the results of a study published in Nature Cell Biology on June 20, and led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, Princess Margaret Cancer Center, the University of Toronto, Harvard Medical School and Oxford University.

Oxygen is important for the proper function of all , but thrive even when deprived of it. Rapid, abnormal cell growth seen in many solid tumors causes them to outgrow their blood supply and leave some cells with less oxygen. In the face of this "hypoxia," cancer cells change their gene expression to turn off all but the most vital oxygen-using processes.

"Our results, by yielding a new understanding of cancer cell response to hypoxia, hopefully will enable the design of future treatments that drive such cells into low-oxygen environments and then take away their ability to survive these conditions," says Benjamin Neel, MD, PhD, director of the Perlmutter Cancer Center.

In the new research, led by Robert Banh, a graduate student in Neel's lab, the investigators found that signals sent by the enzyme protein-tyrosine phosphatase 1B (PTP1B) work in a previously unknown way to shut down oxygen-using processes in deprived of oxygen, thereby enhancing their survival.

Diabetes to Cancer to Moyamoya Disease

Neel and colleagues first identified the gene for protein-tyrosine phosphatase 1B (PTP1B) as part of search for molecules that suppress tumor growth in the early 1990s. PTP1B is the hallmark member of a group of enzymes that take a phosphate group away from biomolecules to turn processes like cell growth on or off.

Neel and colleagues, as well as the group of Michel Tremblay at McGill University, found in earlier studies of mice that PTP1B function was required for the growth in certain cancers. These included breast cancers caused by the Her2 oncogene (HER2+ breast cancer cells), which is implicated in 20 percent of human breast cancers. In more recent work, Banh, Neel and colleagues found that human HER2+ breast cancer cells lacking PTP1B grew normally under standard culture conditions, but died much more rapidly in low oxygen.

Furthermore, researchers found that the three signaling pathways by which cancer cells were known to adapt to hypoxia worked fine in PTP1B-deficient HER2+ breast cancer cells. These included the well-known hypoxia-inducible factor pathway, which shifts the way cells use oxygen from oxidative phosphorylation in cellular "machines" called mitochondria to glycolysis, which does not require oxygen. Instead they found that other non-mitochondrial sources of oxygen consumption were not dialed down appropriately in PTP1B-deficient cells.

The team further found that PTP1B controls the response of tumors in hypoxia by regulating the protein RNF213, which in in turn suppresses by enzymes called α-ketoglutarate-dependent dioxygenases (α-KGDDs). These enzymes use , vitamin C (ascorbic acid) and iron to catalyze myriad reactions.

As the team began to fill in details concerning PTP1B pathway, they realized from the literature that RNF213 was also important in a rare condition called Moyamoya Disease, where patients experience abnormal blood vessel growth in the brain that can lead to blocked arteries and seizures. Conceivably, says Neel, Moyamoya disease symptoms could reflect an abnormal response to hypoxia in vascular cells, and his lab is working to understand the condition's molecular basis.

"We have seen many times in the cancer field that studies of rare syndromes can be being important in explaining mechanisms by which cells respond to stresses," says Neel. "We hope our new study will provide insights into Moyamoya disease that then feed back into our work in cancer biology."

Explore further: New research provides hope for patients with hard-to-treat breast cancer

More information: Nature Cell Biology, DOI: 10.1038/ncb3376

Related Stories

New research provides hope for patients with hard-to-treat breast cancer

June 13, 2016
UK scientists have found a new way to slow the growth of the most aggressive type of breast cancer, according to research published in the journal Oncogene today.

Searching for cancer's fingerprints gives clues to tumour growth

February 25, 2016
A University of Manchester study has shed light on a chain of events that allows tumour cells to thrive in tough environments, identifying potential new ways to diagnose and treat cancer.

How cancer stem cells thrive when oxygen is scarce

March 28, 2016
Working with human breast cancer cells and mice, scientists at The Johns Hopkins University say new experiments explain how certain cancer stem cells thrive in low oxygen conditions. Proliferation of such cells, which tend ...

Promising treatment prospects for invasive breast cancer

June 3, 2016
Scientists from the University of Zurich have been able to understand for the first time why many cancer cells adapt relatively quickly to the treatment with therapeutic antibodies in invasive forms of breast cancer. Instead ...

New signaling pathway discovered in HER2-positive breast cancer, and two powerful drug targets

April 20, 2015
One of the most promising ideas in cancer treatment is to apply a lesson learned in the fight against AIDS (Acquired Immune Deficiency Syndrome): simultaneously attacking a pathological process at different points of weakness ...

Researchers discover mechanism that reverses resistance to antiangiogenic drugs

June 9, 2016
Researchers from the Breast Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) have just published an important finding regarding antiangiogenic drugs, one of the most commonly used drugs ...

Recommended for you

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

Testing the accuracy of FDA-approved and lab-developed cancer genetics tests

December 14, 2017
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug. Clinical tests for common cancer causing-mutations in the genes ...

Newest data links inflammation to chemo-brain

December 14, 2017
Inflammation in the blood plays a key role in "chemo-brain," according to a published pilot study that provides evidence for what scientists have long believed.

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.